Abstract:The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein (MAP) kinase family. The jnk1 and jnk2 genes are expressed ubiquitously, whereas jnk3 has a limited pattern of expression and is largely restricted to brain, heart, and testis. The JNKs signal transduction pathway was shown to play an important role in coordinating various cellular responses including apoptosis, proliferation, and neoplastic transformation. Indiscriminately suppressing the activity of all three c-Jun N-terminal kinase isoforms, JNK1, JNK2, and JNK3, is probably not an appropriate strategy because each JNK appears to have a distinct function in cancer, asthma, diabetes, and Parkinson9s disease. However, until now, isoform selective inhibitors for JNK1 over JNK2 or JNK3 activities have not been developed. Therefore, using structure-based design, we developed (in-house) a selective isoform inhibitor that showed a selective inhibitory effect against JNK1, but not JNK2 or JNK3. We found that 7-(6-N-Phenylaminohexyl)amino-2H-anthra[1,9-cd]pyrazol-6-one (AV-7) suppressed JNK1 activity, with no effect on either JNK2 or JNK3, in vitro. In cell culture systems, we also found that AV-7 inhibited JNK1 activity dose-dependently. In contrast to SP600125, a non-selective JNKs inhibitor, that binds to the ATP active site, AV-7 was designed to target the protein-protein interaction between JNK1 and its binding partner(s) rather than the ATP binding site. At 10 μM, AV-7 specifically inhibited JNK1 by about 50%. The phosphorylation of c-Jun by JNKs induces c-Jun transactivation and transcriptional activity through the formation of a protein complex with c-Fos or ATF1 (i.e., AP-1 complex). c-Jun/AP-1 enhances transcription by binding to the promoter region of many genes. We found that AV-7 inhibits UVB-induced c-Jun phosphorylation and sub-G1 accumulation in JNK2 −/− MEFs, which express only JNK1, but had no effect on c-Jun in JNK1 −/− MEFs, which only express JNK2. These results demonstrate that AV-7 is an isoform selective JNK1 inhibitor. In humans, JNKs play a key role in obesity-induced type 2 diabetes mellitus and the absence of JNK1 results in decreased adiposity, significantly improved insulin sensitivity and an enhanced insulin receptor signaling capacity in mouse obesity models. Therefore, we suggest that because of JNK19s critical role in diabetes, AV-7 might have therapeutic potential against this devastating disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3676.

Supplementary Figure 1 from Licochalcone A, a Natural Inhibitor of C-Jun N-Terminal Kinase 1

Supplementary Table from Licochalcone A, a Natural Inhibitor of c-Jun <i>N</i>-Terminal Kinase 1

Live-cell Imaging and Profiling of C-Jun N-terminal Kinases Using Covalent Inhibitor-Derived Probes.

Lycorine Protects Cartilage Through Suppressing the Expression of Matrix Metalloprotenases in Rat Chondrocytes and in a Mouse Osteoarthritis Model.

Abstract 1034: A natural inhibitor of c-Jun N-terminal kinase 1

Supplemental Figure 3 from Kaempferol Targets RSK2 and MSK1 to Suppress UV Radiation-Induced Skin Cancer

Abstract 3676: A selective small molecule inhibitor of c-Jun N-terminal kinase 1

Inhibition of mitogen-activated protein kinases/nuclear factor κB-dependent inflammation by a novel chalcone protects the kidney from high fat diet-induced injuries in mice.

Supplementary Figure 1 from Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

Design, synthesis and biological evaluation of novel O-substituted tryptanthrin oxime derivatives as c-Jun N-terminal kinase inhibitors

Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts

Microcystin-LR Induces Phosphorylation of p-JNK1/2, P44/42, P38 in Primary Cultured Rat Hepatocytes

Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38.

Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia

Supplementary Figure 2 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

P38 Binds to the Intracellular Precursor of the Lutropin/Choriogonadotropin Receptor and Promotes Its Degradation

KINETICS OF MITOGEN-ACTIVATED PROTEIN KINASE FAMILY IN LIPOPOLYSACCHARIDE-STIMULATED MOUSE KUPFFER CELLS AND THEIR ROLE IN CYTOKINE PRODUCTION

Licochalcone A Inhibits MMPs and ADAMTSs via the NF-κB and Wnt/β-Catenin Signaling Pathways in Rat Chondrocytes

Licochalcone A Inhibits Prostaglandin E2 by Targeting the MAPK Pathway in LPS Activated Primary Microglia

Licochalcone C Inhibits the Growth of Human Colorectal Cancer HCT116 Cells Resistant to Oxaliplatin

Licochalcone B Induces ROS-Dependent Apoptosis in Oxaliplatin-Resistant Colorectal Cancer Cells via p38/JNK MAPK Signaling